Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort)

针对 HPV 相关非艾滋病定义癌症的新型靶向疗法（生物样本/生物队列）

基本信息

批准号：
10620083
负责人：
STEVEN Terry ROSEN
金额：
$ 25万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10620083
关键词：
AIDS related cancer Blood COVID-19 vaccine Cell Death Cell Line Data Dependence Development Engineering Etiology Gene Delivery Gene-Modified Genome Genomics Goals Grant Growth HIV HPV-High Risk Head Cancer Head and Neck Cancer Head and neck structure Human Papilloma Virus-Related Malignant Neoplasm Human Papillomavirus Human papillomavirus 16 Individual Infection Intervention Maintenance Malignant Neoplasms Malignant neoplasm of anus Malignant neoplasm of cervix uteri Methods Mission Modeling Neck Oncogenes Oncogenic Viruses Oncornaviruses Patient Representative Persons Promoter Regions Proteins Public Health RNA delivery Repressor Proteins Research System Testing Therapeutic Therapeutic Intervention United States National Institutes of Health Viral Viral Genes Viral Oncogene Vulnerable Populations Work Zinc Fingers anti-cancer carcinogenicity co-infection combat high risk human papilloma virus oncogene in vivo in vivo Model innovation leukemia lipid nanoparticle mouse model nanoparticle delivery new therapeutic target novel novel therapeutic intervention oncogene addiction patient derived xenograft model success targeted treatment therapeutic RNA therapeutic development therapeutic gene therapeutic target tumor

项目摘要

Project Summary/Abstract Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort) The incidents of non-AIDS-defining cancers (NADC) are increasing in HIV-infected individuals (HIVIIs), urging the development of therapeutic interventions. Many HIV-associated cancers are a result of co-infections with oncogenic viruses, and the high-risk human papillomavirus (HPV) is prevalent in the development of several NADCs, including head-and-neck (HNC) and anal cancers. Importantly, the HPV viral oncogenes are involved in the transformation and maintenance of these cancers and are considered unique targets in HPV-associated malignancies. Often considered `undruggable', these viral genes are susceptible to targeted gene therapeutic strategies and we have developed a novel, potent zinc finger protein (ZFP) that can strongly repress viral oncogenes to elicit anti-cancer effects; a promising approach to HPV-associated NADCs. Furthermore, lipid nanoparticles (LNPs) are a therapeutically relevant non-viral delivery system, which we have used previously for in vivo delivery of RNA-based therapeutics. Importantly, even though the HPV oncogenes represent viable therapeutic targets, there are no studies investigating the potential anti-proliferative effect of targeting the viral oncogenes in HPV-associated tumors from HIVIIs in vivo. Our long-term goal is to develop innovative interventions for the treatment of virally driven cancers emerging in HIVIIs, with the objective of this project to use LNP-delivered ZFP repressors to inactive HPV oncogenes in NADCs. Guided by our strong preliminary data and expertise using targeted repressors and nanoparticle delivery systems, we propose two complementary but distinct objectives, 1) the characterization of novel, potent ZFP repressors for anti-proliferative effects in HPV- associated cell line models relevant to NADCs, and 2) to assess LNP-delivered anti-HPV effectors to inhibit HPV-associated HNCs from HIVIIs in a patient-derived xenograft (PDX) murine model. Collectively, this work will be impactful by developing an innovative targeted repressor to inhibit HPV-associated NADCs, offering a novel intervention to malignancies increasing in HIVIIs.

项目摘要/摘要 HPV相关的非AID定义癌症的新型靶向疗法（Biospecimens/Biocohort）艾滋病毒感染者（HIVII）的非辅助癌症（NADC）的事件正在增加，敦促治疗干预措施的发展。许多与HIV相关的癌症是与共同感染的结果致癌病毒和高风险的人乳头瘤病毒（HPV）在几种发展中普遍存在 NADC，包括头颈（HNC）和肛门癌。重要的是，HPV病毒癌基因涉及在这些癌症的转化和维护中，被认为是与HPV相关的独特目标恶性肿瘤。这些病毒基因通常被认为是“不可能”的，容易受到靶向基因治疗的影响策略，我们开发了一种新型的，有效的锌指蛋白（ZFP），可以强烈抑制病毒癌基因引起抗癌作用； HPV相关的NADC的一种有希望的方法。此外，脂质纳米颗粒（LNP）是一种治疗相关的非病毒输送系统，我们以前已将其用于基于RNA的疗法的体内递送。重要的是，即使HPV癌基因代表可行治疗靶标，没有研究研究靶向病毒的潜在抗增殖作用来自HIVIIS的HPV相关肿瘤中的癌基因体内。我们的长期目标是发展创新治疗病毒驱动的癌症在Hiviis中出现的干预措施，目的是该项目使用LNP传递的ZFP阻遏物在NADC中进行非活性HPV癌基因。在我们强大的初步数据的指导下以及使用有针对性的阻遏物和纳米颗粒输送系统的专业知识，我们提出了两个补充，但独特的目标，1）新型，有效的ZFP阻遏物在HPV-中的抗增殖作用的表征相关的与NADC相关的相关细胞系模型，以及2）评估LNP降低的抗HPV效应子以抑制来自患者衍生异种移植物（PDX）鼠模型中HPV相关的HNC。总的来说，这项工作通过开发创新的目标阻遏物来抑制与HPV相关的NADC，将产生影响对恶性肿瘤的新干预增加了Hiviis。